Oral Immunization of a Non-recombinant Lactococcus Lactis Surface Displaying Influenza Hemagglutinin 1 (HA1) Induces Mucosal Immunity in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Nov 7

PMID 29108012

Citations 7

Authors

Pui-Fong Jee

Vunjia Tiong

Meng-Hooi Shu

Jing-Jing Khoo

Won Fen Wong

Raha Abdul Rahim

Sazaly AbuBakar

Li-Yen Chang

Affiliations

Soon will be listed here.

Abstract

Mucosal immunization of influenza vaccine is potentially an effective approach for the prevention and control of influenza. The objective of the present study was to evaluate the ability of oral immunization with a non-recombinant Lactococcus lactis displaying HA1/L/AcmA recombinant protein, LL-HA1/L/AcmA, to induce mucosal immune responses and to accord protection against influenza virus infection in mice. The LL-HA1/L/AcmA was orally administered into mice and the immune response was evaluated. Mice immunized with LL-HA1/L/AcmA developed detectable specific sIgA in faecal extract, small intestine wash, BAL fluid and nasal fluid. The results obtained demonstrated that oral immunization of mice with LL-HA1/L/AcmA elicited mucosal immunity in both the gastrointestinal tract and the respiratory tract. The protective efficacy of LL-HA1/L/AcmA in immunized mice against a lethal dose challenge with influenza virus was also assessed. Upon challenge, the non-immunized group of mice showed high susceptibility to influenza virus infection. In contrast, 7/8 of mice orally immunized with LL-HA1/L/AcmA survived. In conclusion, oral administration of LL-HA1/L/AcmA in mice induced mucosal immunity and most importantly, provided protection against lethal influenza virus challenge. These results highlight the potential application of L. lactis as a platform for delivery of influenza virus vaccine.

Citing Articles

Intranasally inoculated bacterium-like particles displaying porcine epidemic diarrhea virus S1 protein induced intestinal mucosal immune response in mice.

Su K, Wang Y, Yuan C, Zhang Y, Li Y, Li T Front Immunol. 2023; 14:1269409.

PMID: 37790942 PMC: 10544335. DOI: 10.3389/fimmu.2023.1269409.

A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529.

Chau E, Kwong T, Pang C, Chan L, Chan A, Yao X Int J Mol Sci. 2023; 24(18).

PMID: 37762235 PMC: 10530581. DOI: 10.3390/ijms241813931.

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.

Taghinezhad-S S, Mohseni A, Bermudez-Humaran L, Casolaro V, Cortes-Perez N, Keyvani H Vaccines (Basel). 2021; 9(5).

PMID: 34066443 PMC: 8148110. DOI: 10.3390/vaccines9050466.

Stable Recombinant-Gene Expression from a Live Bacterial Vector via Chromosomal Integration.

Vezina B, Allnutt T, Keyburn A, Wade B, Van T, Johanesen P Appl Environ Microbiol. 2021; 87(11).

PMID: 33741626 PMC: 8208147. DOI: 10.1128/AEM.00392-21.

Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice.

Davarpanah E, Seyed N, Bahrami F, Rafati S, Safaralizadeh R, Taheri T PLoS Negl Trop Dis. 2020; 14(1):e0007939.

PMID: 31899767 PMC: 6941807. DOI: 10.1371/journal.pntd.0007939.

References

Belshe R, Edwards K, Vesikari T, Black S, Walker R, Hultquist M . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96. DOI: 10.1056/NEJMoa065368. View

Varma N, Toosa H, Foo H, Mohamed Alitheen N, Nor Shamsudin M, Arbab A . Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71. Biotechnol Res Int. 2013; 2013:431315. PMC: 3586462. DOI: 10.1155/2013/431315. View

Zhang Q, Zhong J, Huan L . Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Microbiol Res. 2010; 166(2):111-20. DOI: 10.1016/j.micres.2010.02.002. View

Audouy S, van Selm S, van Roosmalen M, Post E, Kanninga R, Neef J . Development of lactococcal GEM-based pneumococcal vaccines. Vaccine. 2006; 25(13):2497-506. DOI: 10.1016/j.vaccine.2006.09.026. View

Lee M, Roussel Y, Wilks M, TABAQCHALI S . Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine. 2001; 19(28-29):3927-35. DOI: 10.1016/s0264-410x(01)00119-0. View

Taylor H, Dimmock N . Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med. 1985; 161(1):198-209. PMC: 2187541. DOI: 10.1084/jem.161.1.198. View

Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C . Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol. 1991; 21(6):1337-44. DOI: 10.1002/eji.1830210602. View

Cox M, Hollister J . FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009; 37(3):182-9. DOI: 10.1016/j.biologicals.2009.02.014. View

Xin K, Hoshino Y, Toda Y, Igimi S, Kojima Y, Jounai N . Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood. 2003; 102(1):223-8. DOI: 10.1182/blood-2003-01-0110. View

10.

Lei H, Peng X, Jiao H, Zhao D, Ouyang J . Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Microb Cell Fact. 2015; 14:111. PMC: 4524015. DOI: 10.1186/s12934-015-0287-4. View

11.

Ahmed B, Loos M, Vanrompay D, Cox E . Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157:H7 in a murine model of colonization. Vaccine. 2014; 32(31):3909-16. DOI: 10.1016/j.vaccine.2014.05.054. View

12.

Czerkinsky C, Svennerholm A, Quiding M, Jonsson R, Holmgren J . Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun. 1991; 59(3):996-1001. PMC: 258358. DOI: 10.1128/iai.59.3.996-1001.1991. View

13.

Mbow M, De Gregorio E, Valiante N, Rappuoli R . New adjuvants for human vaccines. Curr Opin Immunol. 2010; 22(3):411-6. DOI: 10.1016/j.coi.2010.04.004. View

14.

Lei H, Xu Y, Chen J, Wei X, Lam D . Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology. 2010; 407(2):319-24. DOI: 10.1016/j.virol.2010.08.007. View

15.

Buccato S, Maione D, Rinaudo C, Volpini G, Taddei A, Rosini R . Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis. 2006; 194(3):331-40. DOI: 10.1086/505433. View

16.

Liew F, Russell S, Appleyard G, Brand C, Beale J . Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol. 1984; 14(4):350-6. DOI: 10.1002/eji.1830140414. View

17.

Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K . Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine. 2006; 24(18):3900-8. PMC: 7115539. DOI: 10.1016/j.vaccine.2006.02.040. View

18.

Hauri A, Armstrong G, Hutin Y . The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004; 15(1):7-16. DOI: 10.1258/095646204322637182. View

19.

Cox R, Brokstad K, Ogra P . Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004; 59(1):1-15. DOI: 10.1111/j.0300-9475.2004.01382.x. View

20.

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View